This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Emma thumbnail

 

 

 

 

 

Emma - Severe postpartum haemorrhage20

Age: 27 years old

 

Patient characteristics:

Maternal age of 27, BMI 24, first pregnancy, no thrombosis risk factors, haemostatically stable.

Josephine thumbnail

Josephine - Glanzmann's thrombasthenia

 

Age: 15 years old

 

Patient characteristics:

Diagnosed with GT at age of 12 after presenting with HMB, fatigue and dizziness, Lives in a remote location, 45 minutes from HTC, and both parents work full time, still missing 2 days of school per month on average due to HMB.

 

Past medical history:

Iron-deficiency anaemia

Rachel thumbnail

Rachel - Unexplained bruising after giving birth

 

Age: 33 years old

 

Diagnosed with AH

 

Patient characteristics:

BMI of 23, diagnosed with AH when she presented with fatigue and bruising on her limbs and abdomen 10 weeks after the birth of her first child, diagnosis made with prolonged aPTT and normal PT

Jacques thumbnail

Jacques - Breakthrough bleeding despite sub-cutaneous emicizumab

 

Age: 25 years old

 

Patient characteristics:

Switched from pd-aPCC to emicizumab recently, living more actively with higher impact sport, experienced two breakthrough bleeds in the past year. After a long hike, currently experiencing tingling and heat in a knee that was formerly a target joint.

1. NovoSeven® Summary of Product Characteristics, accessed: June 2022.

2. Maahs J et al. J Blood Med. 2014;5:153-156

3. NovoSeven® European public assessment report (EPAR).

4. Fibrinogen Summary of Product Characteristics, accessed: June 2022.

5. Tranexamic Summary of Product Characteristics, accessed: June 2022.

6. Zhang et al. Medicine (Baltimore). 2017;96(45):e8443.

7. Christopoulos et al. J Obstet Gynaecol. 2011;31(2):139-41.

8. Machado et al. N Am J Med Sci. 2011;3(8):358-61.

9. Michelet et al. Gynecol Obstet Fertil. 2015;43(12):773-9.

10. Sihler et al. Chest. 2010;137(1):209-20.

11. Ramler et al. BMC Pregnancy Childbirth. 2017;17(1):197.

12. Taylor et al. Transfus Altern Transfus Med. 2008;10(3):112-26.

13. Thurn et al. Thrombosis Research 165 (2018) 54–60.

14. Hedner U. Blood Rev 2015;29(S1):S4–S8.

15. Demartis F et al. TH Open 2017;1:e130–e138.

16. Lentz SR et al. J Thromb Haemost 2014; 12(8): 1244–1253.

17. Baudo F et al. Blood 2012;120(1):39–46.

18. Di Minno G et al. Haematologica 2015;100(8): 1031–1037.

19. Mariani G et al. Thromb Haemost 2013;109:238–247.

20. Committee for Medicinal Products for Human Use (CHMP), "CHMP extension of indication variation assessment report (NovoSeven(R)), "EPAR", 22 April 2022, Procedure No. EMEA/H/C/000074/II/0116.

21. Hoffman M Dargaud Y. J Thromb Haemost 2012;10:1478–1485.

22. Neufeld EJ et al. Haemophilia 2011;17:650–656.

23. Neufeld EJ et al. Blood Rev 2015;29(S1):S34–S41.

24. Neufeld EJ et al. Haemophilia 2018;24(4):e275–e277.

25. Rexen P et al. TH Open 2019;3:e45–e49.